209 related articles for article (PubMed ID: 33277443)
1. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
Kawakami M; Mustachio LM; Chen Y; Chen Z; Liu X; Wei CH; Roszik J; Kittai AS; Danilov AV; Zhang X; Fang B; Wang J; Heymach JV; Tyutyunyk-Massey L; Freemantle SJ; Kurie JM; Liu X; Dmitrovsky E
Mol Cancer Ther; 2021 Mar; 20(3):477-489. PubMed ID: 33277443
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
Kawakami M; Mustachio LM; Rodriguez-Canales J; Mino B; Roszik J; Tong P; Wang J; Lee JJ; Myung JH; Heymach JV; Johnson FM; Hong S; Zheng L; Hu S; Villalobos PA; Behrens C; Wistuba I; Freemantle S; Liu X; Dmitrovsky E
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376145
[TBL] [Abstract][Full Text] [Related]
3. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.
Hu S; Danilov AV; Godek K; Orr B; Tafe LJ; Rodriguez-Canales J; Behrens C; Mino B; Moran CA; Memoli VA; Mustachio LM; Galimberti F; Ravi S; DeCastro A; Lu Y; Sekula D; Andrew AS; Wistuba II; Freemantle S; Compton DA; Dmitrovsky E
Cancer Res; 2015 May; 75(10):2029-38. PubMed ID: 25808870
[TBL] [Abstract][Full Text] [Related]
4. CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells.
Chen Z; Liu X; Kawakami M; Liu X; Baker A; Bhatawadekar A; Tyutyunyk-Massey L; Narayan K; Dmitrovsky E
Cancer Biol Ther; 2023 Dec; 24(1):2279241. PubMed ID: 38031910
[TBL] [Abstract][Full Text] [Related]
5. Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers.
Kawakami M; Mustachio LM; Liu X; Dmitrovsky E
Mol Cancer Ther; 2018 Apr; 17(4):724-731. PubMed ID: 29559545
[TBL] [Abstract][Full Text] [Related]
6. Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.
Hu S; Lu Y; Orr B; Godek K; Mustachio LM; Kawakami M; Sekula D; Compton DA; Freemantle S; Dmitrovsky E
Mol Cancer Ther; 2015 Nov; 14(11):2576-85. PubMed ID: 26304236
[TBL] [Abstract][Full Text] [Related]
7. TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.
Dmitrovsky E; Kawakami M; Liu XI; Freemantle SJ; Kurie JM
Trans Am Clin Climatol Assoc; 2020; 131():82-94. PubMed ID: 32675848
[TBL] [Abstract][Full Text] [Related]
8. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
[TBL] [Abstract][Full Text] [Related]
9. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
[TBL] [Abstract][Full Text] [Related]
10. Anaphase catastrophe is a target for cancer therapy.
Galimberti F; Thompson SL; Ravi S; Compton DA; Dmitrovsky E
Clin Cancer Res; 2011 Mar; 17(6):1218-22. PubMed ID: 21288923
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.
Zheng L; Chen Z; Kawakami M; Chen Y; Roszik J; Mustachio LM; Kurie JM; Villalobos P; Lu W; Behrens C; Mino B; Solis LM; Silvester J; Thu KL; Cescon DW; Rodriguez-Canales J; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Mol Cancer Ther; 2019 Oct; 18(10):1775-1786. PubMed ID: 31358662
[TBL] [Abstract][Full Text] [Related]
12. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
13. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.
Somarelli JA; Roghani RS; Moghaddam AS; Thomas BC; Rupprecht G; Ware KE; Altunel E; Mantyh JB; Kim SY; McCall SJ; Shen X; Mantyh CR; Hsu DS
Mol Cancer Ther; 2020 Dec; 19(12):2516-2527. PubMed ID: 33158998
[TBL] [Abstract][Full Text] [Related]
14. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
15. 6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2.
Lee DE; Lee KW; Jung SK; Lee EJ; Hwang JA; Lim TG; Kim BY; Bode AM; Lee HJ; Dong Z
Carcinogenesis; 2011 Apr; 32(4):629-35. PubMed ID: 21258042
[TBL] [Abstract][Full Text] [Related]
16. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
Zhu Y; Ke KB; Xia ZK; Li HJ; Su R; Dong C; Zhou FM; Wang L; Chen R; Wu SG; Zhao H; Gu P; Leung KS; Wong MH; Lu G; Zhang JY; Jiang BH; Qiu JG; Shi XN; Lin MC
Mol Med; 2021 Feb; 27(1):15. PubMed ID: 33579185
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
Thomas AL; Lind H; Hong A; Dokic D; Oppat K; Rosenthal E; Guo A; Thomas A; Hamden R; Jeruss JS
Cell Cycle; 2017 Aug; 16(15):1453-1464. PubMed ID: 28678584
[TBL] [Abstract][Full Text] [Related]
18. Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis.
Park SS; Eom YW; Choi KS
Biochem Biophys Res Commun; 2005 Sep; 334(4):1014-21. PubMed ID: 16036217
[TBL] [Abstract][Full Text] [Related]
19. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
Mukhopadhyay P; Ali MA; Nandi A; Carreon P; Choy H; Saha D
Cancer Res; 2006 Feb; 66(3):1758-66. PubMed ID: 16452236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
